P224 REAL-WORLD EVIDENCE OF IMPROVED PATIENT OUTCOMES WITH RESLIZUMAB IN ADULTS WITH SEVERE EOSINOPHILIC ASTHMA (SEA)

M. Wechsler, S. Peters, B. Chipps,T. Hill, R. Ariely,M. DePietro,E. Terasawa,D. Thomason, R. Panettieri

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY（2019）

引用 0|浏览2

暂无评分

摘要

Reslizumab, an anti-interleukin-5 antibody, is approved in the U.S. as add-on therapy for patients with SEA, who typically have elevated eosinophil levels, impaired lung function, and increased risk of clinical asthma exacerbations (CAEs). This study assessed real-world outcomes associated with reslizumab in U.S. clinical practice.

查看译文

关键词

severe eosinophilic asthma,reslizumab,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要